VivoSim Labs, Inc.

VIVS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-13.8M $-2.5M $-14.7M $-17.3M $-11.4M $-16.8M $-18.7M $-26.6M
Depreciation & Amortization $215.0K $266.0K $280.0K $293.0K $142.0K $41.0K $1.1M $980.0K
Depreciation $200.0K $300.0K $300.0K $0 $128.0K $27.0K $1.1M $969.0K
Amortization — — — — — — — —
Stock-Based Compensation — — — — — — — —
Net Cash from Operating Activities $-10.8M $-9.5M $-14.7M $-12.4M $-8.5M $-13.3M $-14.9M $-20.4M
Investing Activities
Capital Expenditures $0 $13.0K $42.0K $396.0K $409.0K $405.0K $0 $79.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $94.0K $9.0M $816.0K $-966.0K $-409.0K $-393.0K $747.0K $-76.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — $0 $1.0K $0 —
Net Cash from Financing Activities $4.4M $8.8M $1.4M $0 $205.0K $23.8M $4.9M $13.2M
Net Change in Cash $-6.3M $8.4M $-12.4M $-13.4M $-8.7M $10.1M $-9.2M $-7.3M
Free Cash Flow $-10.8M $-9.5M $-14.7M $-12.8M $-8.9M $-13.7M $-14.9M $-20.5M
← Newer Page 1 of 2 Older →